Publications by authors named "H LeBlanc"

Introduction: Traumatic injury is the leading cause of pediatric mortality and morbidity in the United States. While behavioral impairments of children after traumatic brain injury (TBI) have been described, outcomes following traumatic spinal cord injury (SCI) and multi-trauma (MT) are less known. We aimed to address the prevalence of behavioral and neuropsychiatric disorders in pediatric and adolescent trauma patients.

View Article and Find Full Text PDF

Forest expansion into savanna is a pervasive phenomenon in West and Central Africa, warranting comparative studies under diverse environmental conditions. We collected vegetation data from the woody and grassy components within 73 plots of 0.16 ha distributed along a successional gradient from humid savanna to forest in Central Africa.

View Article and Find Full Text PDF

Pseudouridine (Ψ) is an ubiquitous RNA modification, present in the tRNAs and rRNAs of species across all domains of life. Conserved pseudouridine synthases modify the mRNAs of diverse eukaryotes, but the modification has yet to be identified in bacterial mRNAs. Here, we report the discovery of pseudouridines in mRNA from E.

View Article and Find Full Text PDF

Engagement of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can interfere with the CD28 signaling requisite for T-cell activation. While immune checkpoint inhibitors (ICIs) can relieve this suppression, they are unable to drive CD28 costimulation that may mechanistically contribute to ICI resistance. Thus, CD28 costimulation in the context of checkpoint inhibition may activate immunosuppressed T-cells in the tumor microenvironment.

View Article and Find Full Text PDF
Article Synopsis
  • - Davoceticept (ALPN-202) is an experimental treatment designed to enhance immune response by targeting PD-L1 and CTLA-4, and its effectiveness was assessed in two studies: NEON-1 (monotherapy) and NEON-2 (in combination with pembrolizumab) on patients with advanced solid tumors.
  • - In NEON-1, 58 participants received varying doses of davoceticept, and in NEON-2, 29 patients received davoceticept alongside pembrolizumab, with safety and efficacy monitored through adverse events and tumor response.
  • - Results indicated that 67% of participants in NEON-1 and 62% in NEON-
View Article and Find Full Text PDF